



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### **Changes in var gene mRNA levels during erythrocytic development in two phenotypically distinct *Plasmodium falciparum* parasites**

**Citation for published version:**

Dahlbäck, M, Lavstsen, T, Salanti, A, Hviid, L, Arnot, DE, Theander, TG & Nielsen, MA 2007, 'Changes in var gene mRNA levels during erythrocytic development in two phenotypically distinct *Plasmodium falciparum* parasites', *Malaria Journal*, vol. 6, no. 78. <https://doi.org/10.1186/1475-2875-6-78>

**Digital Object Identifier (DOI):**

[10.1186/1475-2875-6-78](https://doi.org/10.1186/1475-2875-6-78)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

Malaria Journal

**Publisher Rights Statement:**

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



## Research

## Open Access

### Changes in *var* gene mRNA levels during erythrocytic development in two phenotypically distinct *Plasmodium falciparum* parasites

Madeleine Dahlbäck\*<sup>1</sup>, Thomas Lavstsen<sup>1</sup>, Ali Salanti<sup>1</sup>, Lars Hviid<sup>1</sup>, David E Arnot<sup>1,2</sup>, Thor G Theander<sup>1</sup> and Morten A Nielsen<sup>1</sup>

Address: <sup>1</sup>Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark and <sup>2</sup>Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Scotland, UK

Email: Madeleine Dahlbäck\* - dahlback@cmp.dk; Thomas Lavstsen - thomaslavstsen@vip.cybercity.dk; Ali Salanti - salanti@cmp.dk; Lars Hviid - lhcmp@rh.dk; David E Arnot - d.e.arnot@cmp.dk; Thor G Theander - theander@cmp.dk; Morten A Nielsen - morten.nielsen@rh.regionh.dk

\* Corresponding author

Published: 12 June 2007

Received: 21 March 2007

Malaria Journal 2007, 6:78 doi:10.1186/1475-2875-6-78

Accepted: 12 June 2007

This article is available from: <http://www.malariajournal.com/content/6/1/78>

© 2007 Dahlbäck et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Abstract

**Background:** The *var* multigene family encodes PfEMP1, which are expressed on the surface of infected erythrocytes and bind to various host endothelial receptors. Antigenic variation of PfEMP1 plays a key role in malaria pathogenesis, a process partially controlled at the level of *var* gene transcription. Transcriptional levels, throughout the intra-erythrocytic cycle, of 59 *var* genes of the NF54 clone were measured simultaneously by quantitative real-time PCR. The timing of *var* transcript abundance, the number of genes transcribed and whether transcripts were correctly spliced for protein expression were determined. Two parasite populations were studied; an unselected population of NF54 and a selected population, NF54VAR2CSA, to compare both the transcription of *var2csa* and the expression pattern of the corresponding protein.

**Methods:** Synchronized parasites were harvested at different time points along the 48 hours intra-erythrocytic cycle for extraction of RNA and for analysis of expression of variant surface antigens by flow cytometry. Total RNA from each parasite sample was extracted and cDNA synthesized. Quantitative real-time PCR was performed using gene-specific primers for all *var* genes. Samples for flow cytometry were labelled with rabbit IgG targeting DBL5<sub>E</sub> of VAR2CSA and serum IgG from malaria-exposed men and pregnant women.

**Results:** *var* transcripts were detected at all time points of the intra-erythrocytic cycle by quantitative real-time PCR, although transcription peaked in ring-stage parasites. There was no difference in the timing of appearance of group A, B or C transcripts, and dominant and subdominant *var* transcripts appeared to be correctly spliced at all time points. VAR2CSA appeared on the surface of infected erythrocytes 16 hours after invasion, consistent with previous studies of other PfEMP1. Transcription of the pseudogene *var1csa* could not be detected in NF54VAR2CSA cells.

**Conclusion:** The optimal sampling point for analysis of *var* transcripts using quantitative real-time PCR is the ring-stage, which is encouraging for the analysis of fresh clinical isolates. The data presented here indicate that there is no promiscuous transcription of *var* genes at the individual cell level and that it is possible to correlate dominant transcripts with adhesion phenotype and clinical markers of malaria severity.

## Background

Malaria caused by *Plasmodium falciparum* is a global health problem and the majority of severe clinical cases are found among young children and pregnant women. *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) is a group of variant surface antigens (VSA) expressed on the surface of infected erythrocytes, thus enabling the parasite to sequester in various endothelial tissues of the host and avoid clearance in the spleen [1,2]. Several receptors have been identified as mediators of the sequestration, e.g. CD36 [3], thrombospondin [4] and ICAM-1, associated with cerebral malaria [5] and chondroitin sulfate A (CSA), the main receptor in the placenta and associated with pregnancy-associated malaria (PAM) [6]. PfEMP1 are encoded by the highly diverse *var* gene family and each parasite genome harbours ~60 of these genes [7-9]. The *var* gene repertoire of the 3D7 parasite [10] can be sub-grouped into three major groups (A, B and C), two intermediate groups (B/A and B/C), and the *var1csa* and *var2csa* sub-families based on promoter regions and chromosomal locations [11,12].

VSA appear to be the main target of antibodies conferring protective immunity against malaria [13-17]. However, antigenic diversity and *var* gene switching have made unambiguous identification of the PfEMP1 molecules that are responsible for specific adhesion phenotypes difficult. A quantitative real-time PCR (Q-RT PCR) method was developed to measure the amount of mRNA being transcribed from 59 different NF54/3D7 *var* genes simultaneously [18]. Using this approach, a particular PfEMP1, VAR2CSA, was identified as the parasite ligand likely to be responsible for CSA binding in the placenta [18,19]. In another study using the same method, the group A *var* genes of 3D7 were associated with severe malaria [20,21]. However, correlating expression of *var* genes to the phenotype of a parasite population can yield equivocal results, and studies on *var* gene transcription have given conflicting results regarding both the number of *var* genes being transcribed and the size of these transcripts. Two reverse transcription (RT)-PCR studies suggested that most or all *var* genes are transcribed in ring-stage parasites, whereas in mature trophozoites all but one *var* gene was silenced. Only the *var* gene actively transcribed in late stages would then be translated into protein to confer the phenotype [22,23]. Other studies have proposed that multiple full-length *var* transcripts are present in ring-stage parasites but not in mature stages, with the exception of the *var1csa* gene which was detectable in both trophozoites and later stages [24,25]. A third group of studies detected multiple full-length transcripts in ring-stage and mature trophozoite parasites in both clonal populations [26] and in single cells [27].

To investigate *var* gene mRNA levels in general, and *var2csa* levels in particular, their abundance and quality were determined in two phenotypically different NF54-derived lines using Q-RT PCR throughout the intra-erythrocytic developmental cycle.

## Methods

### In vitro culture

The NF54 clone of *P. falciparum* was cultured as described by Trager and Jensen with modifications [28]. In brief, parasites were maintained in culture using 5% haematocrit of human group O<sup>+</sup> blood in parasite medium consisting of RPMI1640 HEPES medium, supplemented with 25 mmol/L sodium bicarbonate (Sigma-Aldrich), 0.125 g/l gentamicin (Invitrogen), and 0.125 g/l Albumax II (Invitrogen). Culture flasks were maintained in a 37°C incubator and gassed with a mixture of 2% oxygen and 5% carbon dioxide in nitrogen. The parasite lines were confirmed to be monoclonal and of same genotype as 3D7, using nested GLURP, and MSP2-specific primers in a single PCR step.

### Selection of VAR2CSA-expressing parasites

The NF54 parasite isolate was repeatedly selected using VAR2CSA-specific antibodies. Briefly, late-stage trophozoites were obtained by gelatin purification and washed twice in RPMI1640. The infected erythrocytes were then incubated for 0.5 hour at 37°C with VAR2CSA-DBL5ε-specific rabbit antiserum and washed three times with medium to remove unbound antibodies. Infected erythrocytes expressing VAR2CSA were isolated by the use of protein G-coupled magnetic beads (Dynal, Invitrogen) on a MACS magnet (Miltenyi Biotec). The suspension of infected erythrocytes and beads was washed three times and added to a culture flask with 4% haematocrit of uninfected erythrocytes in 5 ml culture medium. After 24 hours, the beads were removed by magnetic separation. This was repeated until parasites specifically expressed VAR2CSA on the surface. Expression of the VSA<sub>PAM</sub> phenotype was confirmed by specific binding of parasites to CSA in static binding assays and exclusive recognition of the surface of the infected erythrocytes by antibodies from women exposed to *P. falciparum* during pregnancy. This was done by flow cytometry using a panel of serum samples from *P. falciparum*-exposed men and women and non-exposed Danes as described [29,30].

NF54 and NF54VAR2CSA cultures were loosely synchronized by gelatin purification of late-stage trophozoites and schizonts. After 48 hours of culture, late-stage trophozoites and schizonts were further enriched on a MACS column to exclude any remaining ring stages, as previously described [31]. This resulted in a synchronous population of parasites with more than 99% late-stage trophozoites and schizonts. Timing of parasite reinvasion was deter-

mined by counting the percentage of ring-stage parasites of 300 infected erythrocytes on thin smears stained by Giemsa (Figure 2). For RNA extractions, each parasite line was cultured in 26 different culture flasks at 1% hematocrit (50  $\mu$ l packed red blood cells) with ~10% parasitaemia after reinvasion. This was done to minimize handling time of the parasite cultures at other time points than during harvesting. The culture was centrifuged and 1 ml of Trizol (Invitrogen) was added to the pellet to preserve RNA. For flow cytometry assays eight different culture flasks were prepared for each isolate. Since separation of ring stages from uninfected erythrocytes is difficult, these cultures were prepared at 0.25% haematocrit with approximately 25% parasitaemia observed after reinvasion to allow for direct staining and flow cytometric analysis.

### Flow cytometry

Flow cytometry was used to assess the timing of VAR2CSA surface expression by each line as described [29,30]. Aliquots of the parasite culture corresponding to  $2 \times 10^5$  infected erythrocytes were labelled by ethidium bromide (to allow exclusion of remaining uninfected erythrocytes). Pools of human sera and rabbit VAR2CSA-specific serum were used for IgG surface-staining of infected erythrocytes. Infected erythrocytes were sequentially exposed to 5  $\mu$ l pooled human serum, and 1  $\mu$ l goat anti-human IgG (Vector) in a total volume of 100  $\mu$ l. For surface staining by

rabbit VAR2CSA DBL5 $\epsilon$ -specific IgG, samples were sequentially exposed to 20  $\mu$ l rabbit serum pre-absorbed against uninfected erythrocytes, 1  $\mu$ l biotinylated sheep anti-rabbit IgG (The Binding Site) and 0.5  $\mu$ l streptavidin-FITC (BD Pharmingen). All incubations were performed in a total volume of 100  $\mu$ l PBS with 2% FCS for 30 min. Samples were washed twice with 3 ml PBS with 2% FCS in between each incubation. Data from a minimum of 5,000 infected erythrocytes were acquired using a FACScan instrument (BD Biosciences). A batch of uninfected erythrocytes was analysed to exclude IgG binding to erythrocyte antigens. All samples relating to a particular time point were stained and processed immediately after removal from the 37°C incubator.

### RNA purification and cDNA synthesis

Synchronized infected erythrocytes were harvested every 2 hours throughout the intra-erythrocytic life cycle for extraction of total RNA and cDNA synthesis as described elsewhere [18]. A representative subset of samples that described the profile of the transcript abundances was further analysed by Q-RT PCR. In brief, 50  $\mu$ l of packed erythrocytes with ~10% parasitaemia was dissolved in 1 ml of Trizol (Invitrogen) and RNA was prepared according to the manufacturer's instruction. RNA pellets were dissolved in 10  $\mu$ l of RNase-free water and treated with DNaseI (Sigma-Aldrich) for 25 min at room temperature,

**Table 1: Specific gene primers used for Q-RT PCR. Primers used to specifically amplify *var* genes, a pseudogene and control genes in Q-RT PCR, in addition to primer sets designed by Salanti et al. [18]. Primers from Salanti et al. that were used in this study (but not shown in table): no. 4–12, 15, 17–23, 25–28, 30, 34–39, 41, 43, 45, 46, 49–55, 91–96, and 97.**

Primer set	Forward primer	Reverse primer	Target gene
1 new	TAAATTGCTCAATCGCGAAG	CATCGTCATCATCGTCATCA	PFA0005w
16	AAAGCCACTAGCGAGGGTAA	TGTTTTGCCCCACTCCTGTA	PFL1955w
24	AGGACAACACGGATGAGACA	AGCAGTGTGTGCGCCATTAG	PFC0005w
32	ACCTAATGGCGAAAACCAAG	ACACTTGCCTTCATCCACTG	PFD1000c
44 new	CCTACACTCACCTCCCCCTA	ACACTCACACGCCTCATCAT	PFF1580c
58 new	ACAACAATTCGCAAGCAAG	TTCCTCTGCCTCCTCTTCAT	PFI1830c
66	CCTAAAAAGGACGCAGAAGG	CCAGCAACACTACCACCAGT	PF08_0107
67	AAGGGAAGATTGGTGACAG	AGGGGGATCAGTATCACGTC	PFF0020c
90 <sup>a</sup>	TCAATTTGATAAAGTGGAACAATTC	GCGTTGTTTAAAGCTCCTGA	PF07_0073
98	ATGGTGGCAAACCTGTGAGA	TCCAATTGGTCTCCTTGACA	PF08_0140
99	AGGGAGCATCAGGTGGTAGT	GCTGTGCATGCTTTTTTCATT	MAL7PI.50
100	GATCAAAAGAGGCGGAGAAG	TTCCAATTGGGGAATTTTTTC	PFI0005w
101	CAAGAGACACAACCGGAAGA	CACTTCCAATTGGGGAATTT	PFA0765c
498/499	AATCAGAAAAGTGTATTGCAGGAG	TTTACTATCATCACTGACACGCATT	MAL7PI.212
500/501	GTCCTCTATGTGGAGTGAAAAAGAA	AGTACCGTTATCTGGGTTTATAGGC	MAL8PI.220
392/393 <sup>b</sup>	AAACGAAAGCGAAGCAGAAT	CACCTTCACTCCTTGCCATA	PFF0005c
334/335	AGCCCAATCGGAAGGTAAGT	TTCATAGCTTCTAGCGCCTT	PFL0030c
UTR var2csa	CACGACATTAACAATACATGCAGA	CATTGCATTCACAGACATTGG	PFL0030c
390/391 <sup>c</sup>	AATAATACCACTGACATTCTGCAAAA	ACACGTAAAAGGTCCACAGGTG	PFL0030c
535/536 <sup>c</sup>	CCAGCAGGACCAGCAACAGATAGTGGC	CCACTTCTATATGGTATGTACCTATTTTTG	PFL0935c
496/497 <sup>c</sup>	AATCACTTCCGCAACCCCCACG	CTGAAAAGGTCCACACGAGG	PFD0615c
MSPI	ACAACCTGAAGATGGGGGTCA	TTTTGGTGGTGATGGTTGTG	PFI1475w

a. Endogeneous control gene, *seryl-tRNA synthetase*.

b. Pseudogene.

c. Primers designed to target flanking regions of the intron (cross-intron primers).

followed by 10 min heat inactivation at 65°C. All RNA samples were subsequently tested in real-time PCR for contamination with genomic DNA using a primer set for the *seryl-tRNA synthetase* gene (Table 1). DNA-free RNA samples were used for synthesis of cDNA by reverse transcriptase (Superscript II, Invitrogen) and random hexamer primers as described by the manufacturer. The cDNA content was confirmed by real-time PCR using primers for the *seryl-tRNA synthetase* gene.

#### Primer design

Transcription of all the *var* genes was determined using primers originally published by Salanti *et al.* [18], although some have since been redesigned (Table 1). Table 1 also contains primers designed to target new *var* genes identified in the *P. falciparum* genome database [32] and primers for additional genes used as controls (*msp1* – PFI1475w and *seryl-tRNA synthetase* – PF07\_0073). All primers were initially tested on genomic DNA to determine the 'amplification efficiency' compared to the amplification of the internal control, *seryl-tRNA synthetase*. Primer pairs that varied more than two Ct values from the Ct value of the internal control were redesigned. Primers for detecting spliced *var* transcripts were designed to target the flanking regions of the intron (cross-intron primers). The 'amplification efficiency' of these cross-intron primers was not determined. However, all cross-intron primers were tested on genomic DNA in conventional PCR with increased elongation time and the PCR products were fractionated by agarose gel electrophoresis. The cross-intron products amplified from cDNA by Q-RT PCR were also fractionated by agarose gel electrophoresis.

#### Quantitative real-time PCR

All Q-RT PCR measurements were performed using the Rotorgene RG-3000 system (Corbett Research). Reactions were prepared in volumes of 20 µl using QuantiTect SYBR Green PCR master mix (QIAGEN) and a primer concentration of 1 µM. The following PCR cycling conditions were used: initial heat activation step at 95°C for 15 min, followed by 40 cycles of 95°C for 30 s, 55°C for 30 s and 68°C for 40 s with a final extension at 68°C for 40 s. The amplification specificity for each primer pair was determined by melting-curve analysis of each PCR product.

#### Quantitative analysis

Gene specific standard curves were generated by determining the 'amplification efficiency' relative to the single copy endogenous control gene (*seryl-tRNA synthetase*), based on real-time measurements of 10-fold dilutions of genomic DNA. Transcript abundance was determined according to the  $\Delta C_t$  (cycle threshold) method, in which the Ct value for each specific gene was compared with that of the endogenous control, and by calculating the relative copy number, based on the specific standard curves

for each gene. Standard curves for the cross-intron primers were not generated.


## Results

### Transcripts of *var* genes were detected throughout the intra-erythrocytic life cycle

Using Q-RT PCR the *var* transcriptome pattern throughout the intra-erythrocytic life cycle was investigated for two parasite cultures, NF54 and NF54VAR2CSA. Figure 1A and 1B show the transcript abundance of 59 full-length *var* genes and two *var* pseudogenes in NF54/3D7 as relative copy numbers normalized to the internal control, *seryl-tRNA synthetase* (PF07\_0073). The percentage of ring-stage parasites was determined by Giemsa staining (Figure 2), in addition to measurements of *msp1* (PFI1475w) transcript abundance to control for stage specificity of each parasite population (Figure 1A and 1B). For both cultures there was a clear peak in transcript abundance at ring stage, ~5–25 hours after invasion. Figure 1C shows the transcript abundance of each full-length *var* gene relative to total number of *var* transcripts, in which the proportion of the most abundant transcript was higher at ring stage compared to the schizont stage.

The most abundant *var* transcript in NF54 ring-stage parasites was PFL0935c (Figure 1A and 1C), which in the 3D7 genome is a centromeric *var* gene on chromosome 12 with a group B 5' UTR promoter according to the grouping of 3D7 *var* genes [10–12]. Two additional *var* genes were transcribed at high levels in NF54, PFL1960w (group C, localized on chromosome 12 in the 3D7 genome) and PF08\_0106 (group B/C, on chromosome 8). By contrast, NF54VAR2CSA represents a highly homogeneous population, which transcribes almost solely *var2csa* (PFL0030c, on chromosome 12). All other *var* genes were transcribed at low levels or below the detection level (Figure 1B). Three primer sets targeting DBL2, DBL4, and the 5' UTR of *var2csa*, were used and the results obtained with these primers were tightly correlated (Figure 1B). Transcripts of *var2csa* were also detected in the unselected NF54 at low levels, similar to those of the less abundant *var* mRNA

The transcriptional time profile of *var2csa* appeared slightly different from the other *var* genes. This is most evident in Figure 3 showing relative copy numbers of the most abundant *var* transcript as well as total *var* transcripts in both populations. The transcript abundance peak of *var2csa* in both parasite populations emerges slightly earlier in the ring stage of the parasite development and also declines faster than for the other *var* genes (Figure 1A and 3). In addition, the broad transcript abundance peak in NF54 seems to consist of two waves, a pattern which was observed for all the *var* genes (Figure 1A and 3). No differences between the various *var* gene groups (A, B and C)

**Figure 1**

**Transcriptional profiles of NF54/3D7 *var* genes in two phenotypically different parasites.** Quantification of all the *var* transcripts normalized against *seryl-tRNA synthetase* and shown as log<sub>10</sub>(relative copy number) in (A) and (B) and as pie charts in (C) at different time points during the intra-erythrocytic life cycle of NF54 and NF54VAR2CSA. (C) shows only expression of full-length *var* genes. (A) and (B): blue – *msp1* (was used for monitoring the different stages), green – PFL0935c (dominant transcript in NF54), grey – *var1csa*, red diamonds – *var2csa* (DBL4 primers), red circles – *var2csa* (DBL2 primers), red rectangles – *var2csa* (5' UTR primers). (C): light green – PFL0935c, red – *var2csa* (DBL2 primers). pi – post invasion


were detected regarding appearance and disappearance of transcripts.

The transcript abundance of two truncated sub-telomeric *var* pseudogenes of NF54/3D7, *var1csa* (PFE1640w, on chromosome 5, lacks intron and exon II) and PFF0005c (group A pseudogene, on chromosome 6, truncated in DBL1α), was also determined. *var1csa*, which has been found to be constitutively transcribed in many parasites irrespective of binding phenotype [25], was constitutively transcribed at high levels in NF54 but barely detected in NF54VAR2CSA (Figure 1A and 1B, respectively). The more recently discovered *var* pseudogene, PFF0005c, was

detected at a few time points at very low levels in both isolates.

#### **Dominant and subdominant *var* genes are transcribed as spliced mRNA throughout the intra-erythrocytic life cycle**

To investigate whether *var* transcripts are correctly spliced throughout the intra-erythrocytic life cycle, specific cross-intron primers were designed (Table 1) for the dominant (most abundant) gene in each isolate (PFL0935c and *var2csa*) and a variant that was subdominant (less abundant) in both parasite populations (PFD0615c, group C, on chromosome 4). The transcript abundance profiles measured by the cross-intron primers targeting the domi-



**Figure 2**  
**Percentage of ring-stage parasites in the synchronized populations.** The percentage of ring-stage parasites in the NF54 and NF54VAR2CSA population was determined by Giemsa staining for different time points along the cycle.

nant and subdominant genes were similar to the profiles given by the corresponding exon I primers. This indicates both that the two sets of primers were recognizing the same transcript and that most, if not all, detectable transcripts were already spliced (Figure 4). The difference in  $\Delta C_t$  value between the primer sets for PFL0935c (Figure 4A) was most likely due to differential primer bias.

#### Timing of VAR2CSA expression on the surface of NF54VAR2CSA

Parasites from infected placentae and CSA-selected late-stage parasites are recognized by human immune sera in a sex-specific manner. This was also the case for NF54VAR2CSA (Figure 5B). As expected, there was no difference in the recognition of unselected NF54 by female and male sera (Figure 5A). The flow cytometry data confirmed published findings that VAR2CSA, like other PfEMP1, appears on the surface of infected erythrocytes several hours after the first detection of *var* transcription (Figure 1B and 5B). Surface-exposed VAR2CSA was detected by VAR2CSA-specific rabbit antibodies and female serum from a malaria endemic area about 18 hours after invasion, and the amount of PfEMP1 reached a plateau which seemed to remain constant throughout the later stages. Male immune sera, on the other hand, showed the same lack of recognition of NF54VAR2CSA as was seen in unselected NF54.

#### Discussion

Transcript levels of *var* genes were analyzed throughout asexual parasite development using an improved version of the Q-RT PCR method originally published by Salanti


*et al.* [18]. Primer pair coverage was extended to optimize quantitative measurement of mRNA transcribed from 59 full-length *var* genes and two pseudogenes in the NF54/3D7 genome. Two phenotypically distinct NF54-derived lines, NF54 (unselected) and NF54VAR2CSA (selected for VAR2CSA expression) showed abundance peaks of dominant and subdominant *var* transcripts at ring stage, although the relative abundance of the dominant transcript in each population was higher in ring stage and early trophozoites than in schizonts. This can be explained by the increased uncertainty of measurement when transcript abundance is very low.

Unselected NF54 parasites are clearly a mixture of subpopulations expressing different *var* genes (Figure 1). However, after repeated selection, the *var2csa* gene has become the overwhelmingly dominant transcript and constitutes >98% of all detected *var* transcripts. This pattern of exclusive expression of the *var2csa* gene (Figure 1C) supports the general model of mutually exclusive transcription of *var* genes. Such a general model was proposed after experiments showed that exclusive transcription of activated group B and C 5' UTR promoters occurred following transfection [33,34]. It is likely that a significant proportion of the unselected ring-stage NF54 is exclusively expressing the dominant group B *var* transcript. However, this is not as apparent in this line as in the NF54VAR2CSA due to the heterogeneity of this unselected population. While it remains to be proven that *var* transcription in circulating parasites in the bloodstream can always be correlated to the binding phenotype of the corresponding trophozoite population, this study supports such a conclusion. Another recent study has shown that the genotypes of the circulating ring-stage parasites represent the types of the mature parasites sequestering in most tissues [35].

Improved quantification of transcript abundances of each *var* gene obtained by Q-RT PCR and use of cross-intron primers also support a revision of the view that *var* transcripts are exclusively restricted to the ring stage and that there is promiscuous transcription of many *var* genes in ring-stage parasites [24,36]. New data, reported here and in other recent publications [37], indicate that the so-called 'loose' transcription of several *var* transcripts per infected erythrocyte results from cross-hybridization artefacts and the background of gene expression from minority populations in cultures which are not expressing the dominant, selected *var* gene.

Truncated or unspliced transcripts in parasites have also been reported [8,38]. In this study, cross-intron primers for three different *var* genes, *var2csa* (PFL0030c), a group B gene (PFL0935c) and a group C gene (PFD0615c) all showed splicing of exon I to exon II in both the unselected





**Figure 3**  
**Total number of *var* transcripts in NF54 and NF54VAR2CSA.** Total *var* transcription is shown as relative copy number for both NF54 and NF54VAR2CSA. Total *var* transcription of both populations corresponds to the expression of the most abundant transcript, PFL0935c and *var2csa* (PFL0030c), respectively. The most striking difference in transcription is the slightly earlier distinctive peak for *var2csa* (PFL0030c) in NF54VAR2CSA compared to the broader wave-like appearance of *var* transcription in NF54. All measurements at the different time points were normalized against *seryl-tRNA synthetase*.

and VAR2CSA-selected NF54 parasites throughout the whole cycle, indicating that these *var* genes are normally expressed as correctly spliced transcripts (Figure 4). The fact that the transcription levels of the four different *var2csa*-specific primers were tightly correlated further indicates that the transcripts are not only correctly spliced but also probably full-length at all stages. This is contrary to a conclusion drawn in an earlier study in which a difference between the levels of transcription detected by cross-intron primers and exon I primers of some *var* genes using Q-RT PCR were reported [38]. This discrepancy could be due to the 'amplification bias' of the cross-intron primers, and the difficulties of designing unique primers targeting the exon II. However it is worth noting that promiscuous transcription in any form is incompatible with transfection experiments showing the exclusive expression of a single *var* gene regulated at a pre-transcriptional level [33,34,39,40].

It has also been suggested that there is a differential repression of the various *var* gene groups based on their promoters [41]. The group B genes (subtelomeric) were shown to be transcribed 0–10 hours after invasion, and turned off


when the parasites reached later stages, whereas the group C (chromosome-central) transcripts were still detected 4–8 hours later than the subtelomeric genes. This differential transcription pattern was not seen here. All *var* genes within group A, B or C in the unselected NF54 population showed the same abundance profile regardless of promoter.

Both *var1csa* and *var2csa* have unique promoters (group D and E respectively, [11,12], and both these genes showed distinctive expression profiles. *var1csa* transcription remains anomalous and poorly understood. *var1csa* was constitutively transcribed in the unselected NF54 line, a result reported previously for several *P. falciparum* isolates, regardless of their receptor binding phenotype [25,38,42]. However, *var1csa* transcription was not detected in any stages in NF54VAR2CSA. This observation is most simply explained by a *var1csa*-expressing subpopulation of NF54 having been removed by VAR2CSA selection. This interpretation further entails that only one *var* gene is transcribed per infected erythrocyte and the *var1csa* gene is restrained from transcription by the silencing mechanisms operating on all *var* genes that is imposed when another *var* gene, in this case *var2csa*, is expressed.

The essentially exclusive expression of a single *var* gene that is observed in the NF54VAR2CSA parasites, where *var2csa* constitutes 98% of total *var* gene abundance, has previously only been observed in *P. falciparum* cultures transfected with drug-selectable marker genes [33,34]. In these experiments, transgenic parasite lines use a *var* promoter to drive expression of a drug resistance gene rather than a PfEMP1 protein. Drug selection followed by cloning and analysis of resistant lines indicates that the transfected recombinant promoter is activated in these lines and that all other *var* promoters are silenced. There is disagreement as to whether a single active *var* promoter is sufficient to silence all other promoters [34] or whether the system of allelic exclusion requires both the 5' *var* promoter and a promoter located downstream in the *var* gene intron to interact in some way to silence transcription [43,44].

Transcription of *var1csa* in the unselected NF54 presumably results from a subpopulation of parasites in which other *var* genes are silenced. The relatively constitutive transcription of *var1csa* may result from a dysfunction of the transcriptional regulation related to the cell cycle. As *var1csa* has an upstream promoter but is truncated at exon I, it can be hypothesized that its 5' UTR promoter, as previously demonstrated [34] is needed for exclusive transcription of a single *var* gene whereas the intron/exon II/3' UTR is needed for the observed wave shaped transcriptional regulation throughout the cell cycle. Yet, the abundance profile of *var1csa* during the complete intra-





**Figure 4**  
**Both dominant and subdominant *var* genes seem to be correctly spliced throughout the whole intra-erythrocytic life cycle.** Transcript abundance measured by cross-intron primers and exon I primers for the dominant and two subdominant *var* genes are shown as  $\Delta$ Ct values for (A) NF54 and (B) NF54VAR2CSA.

erythrocytic cycle in other isolates than 3D7 and NF54 remains unclear, and more studies are needed to elucidate the role of this *var* gene. Furthermore, it is not known whether the apparent lack of other pseudogene-transcribing subpopulations, here represented by PFF0005c, can be related to the difference in the 5' UTR promoter.


*var2csa* had a pattern of changes in mRNA abundance similar to that of the other *var* genes being transcribed in the unselected NF54 line. However, the abundance profile indicated that its transcription peaks earlier in the ring stage than the other *var* genes. Since the timing of the cycle of both lines were tightly correlated according to the Giemsa stain assessment, this observation is probably not due to major differences in synchronization. The protein expression of VAR2CSA did not seem to diverge from earlier reports showing that PfEMP1 molecules appear to be present on the infected erythrocyte membrane around 16–18 hours after invasion [45–47]. As expected, the recognition pattern of NF54VAR2CSA by rabbit antibodies raised against recombinant-produced DBL5 $\epsilon$  of VAR2CSA was correlated with the recognition of the immune sera of malaria-exposed multi-gravidae women from a malaria endemic area.

## Conclusion

*var* transcription can be measured by Q-RT PCR at all stages throughout the intra-erythrocytic life cycle. However, to identify the dominant transcript in a parasite population it is critical to perform the analysis on ring-stage parasites when transcript levels peak. The findings that a highly homogeneous parasite population transcribes essentially one *var* gene at all time points and that the *var2csa* gene, a group B *var* gene and a group C *var* gene are all expressed as correctly spliced transcripts at all intra-erythrocytic stages suggest that previous reports of promiscuous transcription of many *var* genes in a single parasite might represent experimental artefacts resulting from the presence of heterogeneous parasite populations.

## Authors' contributions

MD carried out the RNA extractions, cDNA synthesis and all the Q-RT PCR experiments, analysed the data and wrote the manuscript. TL participated in the design of the study, helped with primer design, the Q-RT PCR and to draft the manuscript. AS contributed to the study design and helped to draft the manuscript. LH, DEA and TGT helped to finalise the manuscript. MAN participated in the study design, carried out all the parasite work and flow

**Figure 5**

**Timing of VAR2CSA surface expression.** Surface staining of infected erythrocytes selected with VAR2CSA-specific rabbit antibodies, NF54VAR2CSA, and the unselected control, NF54. The median of FITC fluorescence as measured by flow cytometry is shown for each serum sample. Pools of human sera from *P. falciparum* exposed females and males, and unexposed Danes (DK-pool) were used as primary antibodies. VAR2CSA expression was confirmed by staining with VAR2CSA DBL5ε-specific rabbit antibodies and irrelevant rabbit immune serum was used as negative control. Samples were processed and run simultaneously at individual time points.

cytometry experiments and helped to finalise the manuscript. All authors read and approved the final manuscript.

### Acknowledgements

MD is supported by a PhD studentship from the Danish Research Council for Development Research (RUF). AS is supported by a postdoctoral grant from the Danish Medical Research Council (SSVF). MAN is supported by a postdoctoral grant from Hovedstadens Sygehusfællesskab.

### References

- David PH, Hommel M, Miller LH, Udeinya JJ, Oligino LD: **Parasite sequestration in *Plasmodium falciparum* malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes.** *Proc Natl Acad Sci USA* 1983, **80**:5075-5079.
- Howard RJ, Barnwell JW: **Roles of surface antigens on malaria-infected red blood cells in evasion of immunity.** *Contemp Top Immunobiol* 1984, **12**:127-200.
- Ockenhouse CF, Tandon NN, Magowan C, Jamieson GA, Chulay JD: **Identification of a platelet membrane glycoprotein as a *falciparum* malaria sequestration receptor.** *Science* 1989, **243**:1469-1471.
- Roberts DD, Sherwood JA, Spitalnik SL, Panton LJ, Howard RJ, Dixit VM, Frazier WA, Miller LH, Ginsburg V: **Thrombospondin binds *falciparum* malaria parasitized erythrocytes and may mediate cytoadherence.** *Nature* 1985, **318**:64-66.
- Berendt AR, Simmons DL, Tansey J, Newbold CI, Marsh K: **Inter cellular adhesion molecule-1 is an endothelial cell adhesion receptor for *Plasmodium falciparum*.** *Nature* 1989, **341**:57-59.
- Fried M, Duffy PE: **Adherence of *Plasmodium falciparum* to chondroitin sulfate A in the human placenta.** *Science* 1996, **272**:1502-1504.
- Baruch DI, Pasloske BL, Singh HB, Bi XH, Ma XC, Feldman M, Taraschi TF, Howard RJ: **Cloning the *Plasmodium falciparum* gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes.** *Cell* 1995, **82**:77-87.
- Su XZ, Heatwole VM, Wertheimer SP, Guinet F, Herrfeldt JA, Peterson DS, Ravetch JA, Wellems TE: **The large diverse gene family *var* encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes.** *Cell* 1995, **82**:89-100.
- Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, Peterson DS, Pinches R, Newbold CI, Miller LH: **Switches in expression of *Plasmodium falciparum* *var* genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes.** *Cell* 1995, **82**:101-110.
- Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA,

- Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shalom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B: **Genome sequence of the human malaria parasite *Plasmodium falciparum*.** *Nature* 2002, **419**:498-511.
11. Lavstsen T, Salanti A, Jensen ATR, Arnot DE, Theander TG: **Subgrouping of *Plasmodium falciparum* 3D7 var genes based on sequence analysis of coding and non-coding regions.** *Malaria Journal* 2003, **2**:27.
12. Kraemer SM, Smith JD: **Evidence for the importance of genetic structuring to the structural and functional specialization of the *Plasmodium falciparum* var gene family.** *Mol Microbiol* 2003, **50**:1527-1538.
13. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM: **Antibodies to blood stage antigens of *Plasmodium falciparum* in rural Gambians and their relation to protection against infection.** *Trans R Soc Trop Med Hyg* 1989, **83**:293-303.
14. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K: **Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria.** *Nat Med* 1998, **4**:358-360.
15. Ofori MF, Dodoo D, Staalsoe T, Kurtzhals JAL, Koram K, Theander TG, Akanmori BD, Hviid L: **Malaria-induced acquisition of antibodies to *Plasmodium falciparum* variant surface antigens.** *Infect Immun* 2002, **70**:2982-2988.
16. Duffy PE, Fried M: **Antibodies that inhibit *Plasmodium falciparum* adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of Newborns.** *Infect Immun* 2003, **71**:6620-6623.
17. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L: **Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated *Plasmodium falciparum* malaria.** *Lancet* 2004, **363**:283-289.
18. Salanti A, Staalsoe T, Lavstsen T, Jensen ATR, Sowa MPK, Arnot DE, Hviid L, Theander TG: **Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering *Plasmodium falciparum* involved in pregnancy-associated malaria.** *Mol Microbiol* 2003, **49**:179-191.
19. Salanti A, Dahlback M, Turner L, Nielsen MA, Barford L, Magistrado P, Jensen ATR, Lavstsen T, Ofori MF, Marsh K, Hviid L, Theander TG: **Evidence for the involvement of VAR2CSA in pregnancy-associated malaria.** *J Exp Med* 2004, **200**:1197-1203.
20. Jensen ATR, Magistrado P, Sharp S, Joergensen L, Lavstsen T, Chiucciini A, Salanti A, Vestergaard LS, Lusingu JP, Hermesen R, Sauerwein R, Christensen J, Nielsen MA, Hviid L, Sutherland C, Staalsoe T, Theander TG: ***Plasmodium falciparum* associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes.** *Journal of Experimental Medicine* 2004, **199**:1179-1190.
21. Magistrado PA, Lusingu J, Vestergaard LS, Lemnge M, Lavstsen T, Turner L, Hviid L, Jensen AT, Theander TG: **IgG antibody reactivity to a Group A PfEMP1 and protection from *Plasmodium falciparum* malaria.** *Infect Immun* 2007, **75**:2415-2420.
22. Scherf A, Hernandez-Rivas R, Buffet P, Bottius E, Benatar C, Pouvelle B, Gysin J, Lanzer M: **Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra-erythrocytic development in *Plasmodium falciparum*.** *EMBO J* 1998, **17**:5418-5426.
23. Chen QJ, Fernandez V, Sundstrom A, Schlichterle M, Datta S, Hagblom P, Wahlgren M: **Developmental selection of var gene expression in *Plasmodium falciparum*.** *Nature* 1998, **394**:392-395.
24. Kyes S, Pinches R, Newbold C: **A simple RNA analysis method shows var and rif multigene family expression patterns in *Plasmodium falciparum*.** *Mol Biochem Parasitol* 2000, **105**:311-315.
25. Kyes SA, Christodoulou Z, Raza A, Horrocks P, Pinches R, Rowe JA, Newbold CI: **A well-conserved *Plasmodium falciparum* var gene shows an unusual stage-specific transcript pattern.** *Mol Microbiol* 2003, **48**:1339-1348.
26. Noviyanti R, Brown GV, Wickham ME, Duffy MF, Cowman AF, Reeder JC: **Multiple var gene transcripts are expressed in *Plasmodium falciparum* infected erythrocytes selected for adhesion.** *Mol Biochem Parasitol* 2001, **114**:227-237.
27. Duffy MF, Brown GV, Basuki W, Krejany EO, Noviyanti R, Cowman AF, Reeder JC: **Transcription of multiple var genes by individual, trophozoite-stage *Plasmodium falciparum* cells expressing a chondroitin sulphate A binding phenotype.** *Mol Microbiol* 2002, **43**:1285-1293.
28. Trager W, Jensen JB: **Human malaria parasites in continuous culture.** *Science* 1976, **193**:673-675.
29. Staalsoe T, Giha HA, Dodoo D, Theander TG, Hviid L: **Detection of antibodies to variant antigens on *Plasmodium falciparum*-infected erythrocytes by flow cytometry.** *Cytometry* 1999, **35**:329-336.
30. Ricke CH, Staalsoe T, Koram K, Akanmori BD, Riley EM, Theander TG, Hviid L: **Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on *Plasmodium falciparum*-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A.** *J Immunol* 2000, **165**:3309-3316.
31. Paul F, Roath S, Melville D, Warhurst DC, Osisanya JO: **Separation of malaria-infected erythrocytes from whole blood: use of a selective high-gradient magnetic separation technique.** *Lancet* 1981, **2**:70-71.
32. PlasmoDB - The Plasmodium Genome Resource [<http://www.plasmodb.org>]
33. Dzikowski R, Frank M, Deitsch K: **Mutually exclusive expression of virulence genes by malaria parasites is regulated independently of antigen production.** *PLoS Pathog* 2006, **2**:e22.
34. Voss TS, Healer J, Marty AJ, Duffy MF, Thompson JK, Beeson JG, Reeder JC, Crabb BS, Cowman AF: **A var gene promoter controls allelic exclusion of virulence genes in *Plasmodium falciparum* malaria.** *Nature* 2006, **439**:1004-1008.
35. Dembo EG, Phiri HT, Montgomery J, Molyneux ME, Rogerson SJ: **Are *Plasmodium falciparum* parasites present in peripheral blood genetically the same as those sequestered in the tissues?** *Am J Trop Med Hyg* 2006, **74**:730-732.
36. Taylor HM, Kyes SA, Harris D, Kriek N, Newbold CI: **A study of var gene transcription in vitro using universal var gene primers.** *Mol Biochem Parasitol* 2000, **105**:13-23.
37. Kyes S, Christodoulou Z, Pinches R, Kriek N, Horrocks P, Newbold C: ***Plasmodium falciparum* var gene expression is developmentally controlled at the level of RNA polymerase II-mediated transcription initiation.** *Mol Microbiol* 2007, **63**:1237-1247.
38. Duffy MF, Byrne TJ, Elliott SR, Wilson DW, Rogerson SJ, Beeson JG, Noviyanti R, Brown GV: **Broad analysis reveals a consistent pattern of var gene transcription in *Plasmodium falciparum* repeatedly selected for a defined adhesion phenotype.** *Mol Microbiol* 2005, **56**:774-788.
39. Duraisingh MT, Voss TS, Marty AJ, Duffy MF, Good RT, Thompson JK, Freitas-Junior LH, Scherf A, Crabb BS, Cowman AF: **Heterochromatin silencing and locus repositioning linked to regulation of virulence genes in *Plasmodium falciparum*.** *Cell* 2005, **121**:13-24.
40. Ralph SA, Scheidig-Benatar C, Scherf A: **Antigenic variation in *Plasmodium falciparum* is associated with movement of var loci between subnuclear locations.** *Proc Natl Acad Sci USA* 2005, **102**:5414-5419.
41. Voss TS, Kaestli M, Vogel D, Bopp S, Beck HP: **Identification of nuclear proteins that interact differentially with *Plasmodium falciparum* var gene promoters.** *Mol Microbiol* 2003, **48**:1593-1607.
42. Winter G, Chen QJ, Flick K, Kremsner P, Fernandez V, Wahlgren M: **The 3D7var5.2 (var COMMON) type var gene family is commonly expressed in non-placental *Plasmodium falciparum* malaria.** *Mol Biochem Parasitol* 2003, **127**:179-191.
43. Gannoun-Zaki L, Jost A, Mu JB, Deitsch KW, Welles TE: **A silenced *Plasmodium falciparum* var promoter can be activated in vivo through spontaneous deletion of a silencing element in the intron.** *Eukaryot Cell* 2005, **4**:490-492.
44. Frank M, Dzikowski R, Costantini D, Amulic B, Berdugo E, Deitsch K: **Strict pairing of var promoters and introns is required for var gene silencing in the malaria parasite *Plasmodium falciparum*.** *J Biol Chem* 2006, **281**:9942-9952.
45. Gardner JP, Pinches RA, Roberts DJ, Newbold CI: **Variant antigens and endothelial receptor adhesion in *Plasmodium falciparum*.** *Proc Natl Acad Sci USA* 1996, **93**:3503-3508.
46. Waterkeyn JG, Wickham ME, Davern KM, Cooke BM, Coppel RL, Reeder JC, Culvenor JG, Waller RF, Cowman AF: **Targeted muta-**

genesis of *Plasmodium falciparum* erythrocyte membrane protein 3 (PfEMP3) disrupts cytoadherence of malaria-infected red blood cells. *EMBO J* 2000, **19**:2813-2823.

47. Kriek N, Tilley L, Horrocks P, Pinches R, Elford BC, Ferguson DJP, Lingelbach K, Newbold CI: **Characterization of the pathway for transport of the cytoadherence-mediating protein, PfEMP1, to the host cell surface in malaria parasite-infected erythrocytes.** *Mol Microbiol* 2003, **50**:1215-1227.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

